Citation:Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, et al 2014

Citation

Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 2014 May;15(6):569-79 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24739896.

Critical appraisals

• Assign a critical appraisal

Cited by

1. Role of biological agents in first-line treatment of metastatic colorectal cancer
2. Systemic options for third-line treatment